Daniel D. Von Hoff, MD, FACP

Clinical Advisor

• Physician in Chief, Distinguished Professor, Director of Clinical Translational Research Division at TGen

• CSO, US Oncology Research

• Professor of Medicine, Mayo Clinic, Scottsdale, AZ

• Recognized expert in Oncology drug development

• PI on numerous phase I-III clinical trials including Abraxane; >620 papers, 137 book chapters

• 2010 David A. Karnofsky Memorial Award from ASCO; Past President of the AACR; Appointed to President
  Bush’s National Cancer Advisory Board in 2004-2010

• Founder of ILEX™ Oncology

Sant Chawla, MD, FRACP

Clinical Advisor

• Director, Sarcoma Oncology Center, Santa Monica, CA

• Academic appointments and affiliations: Stanford Univ Medical Center, MD Anderson Cancer Center, David
  Geffen School of Medicine UCLA, Keck School of Medicine USC, Cedars Sinai Medical Center

• Extensive Clinical trial experience (>30 yrs) : Phase 1-3. Pazopanib, Denosumab, Ridoforolimus (rapamycin
  analog), Palifosfomide, Aldoxorubicin, TH302, belinostat, ofatumumab, AMG655, MEK162 and others